|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Bad Bugs, Few Drugs
Even as physicians scramble to keep ahead of the latest drug-resistant pathogens, new antibiotics are in short supply, and the pipeline for future products is alarmingly thin. Miller explains why R&D for new antibiotics has grown scarce, and suggests how policymakers can encourage companies to expand their efforts in this vital area.
Even as we speculate about the likelihood of a pandemic of avian flu and anticipate the beginning of the season of West Nile virus infections, the United States is experiencing another perilous epidemic. As many as 2 million patients nationwide contract bacterial infections in hospitals each year, and 90,000 die, according to the Centers for Disease Control and Prevention (CDC). The death rate in such cases is alarmingly high not because the patients are initially very ill, but because hospital germs increasingly are resistant to multiple antibiotics. Thus, the infections are difficult to treat.
|home spotlight commentary research events news about contact links archives|